Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial
Abu Dhabi, Uae (ots/PRNewswire) - Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people with type 2 diabetes whose blood sugar was not controlled on insulin glargine U100 with ...